pre-seed
Stage
About
Calyxha is a private biotechnology company developing novel small-molecule anti-inflammatory drugs, with its lead candidate CAL-4 aiming to offer a corticosteroid alternative for asthma currently in preclinical development and planned for clinical entry by 2024.
Explore Calyxha's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.